S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
Log in
NASDAQ:SYRS

Syros Pharmaceuticals Stock Forecast, Price & News

$14.10
+0.27 (+1.95 %)
(As of 01/15/2021 12:00 AM ET)
Add
Compare
Today's Range
$13.44
Now: $14.10
$14.99
50-Day Range
$7.64
MA: $10.85
$14.66
52-Week Range
$4.26
Now: $14.10
$15.65
Volume803,143 shs
Average Volume716,887 shs
Market Capitalization$792.42 million
P/E RatioN/A
Dividend YieldN/A
Beta2.01
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subset of patients with acute myeloid leukemia and myelodysplastic syndrome; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. It has target discovery, research collaboration, and option agreement with Incyte Corporation to identify therapeutic targets with a focus on myeloproliferative neoplasms; and a license agreement with TMRC Co. Ltd. for the development and commercialization of tamibarotene. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was founded in 2011 and is headquartered in Cambridge, Massachusetts.
Syros Pharmaceuticals logo

MarketRank

Overall MarketRank

1.15 out of 5 stars

Analyst Opinion: 2.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SYRS
CUSIPN/A
Phone617-744-1340
Employees83

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.98 million
Book Value$1.87 per share

Profitability

Net Income$-75,440,000.00
Net Margins-743.58%

Miscellaneous

Market Cap$792.42 million
Next Earnings Date3/4/2021 (Estimated)
OptionableOptionable
$14.10
+0.27 (+1.95 %)
(As of 01/15/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive SYRS News and Ratings via Email

Sign-up to receive the latest news and ratings for SYRS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Syros Pharmaceuticals (NASDAQ:SYRS) Frequently Asked Questions

How has Syros Pharmaceuticals' stock price been impacted by Coronavirus (COVID-19)?

Syros Pharmaceuticals' stock was trading at $5.15 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, SYRS stock has increased by 173.8% and is now trading at $14.10.
View which stocks have been most impacted by COVID-19
.

Is Syros Pharmaceuticals a buy right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Syros Pharmaceuticals in the last year. There are currently 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Syros Pharmaceuticals stock.
View analyst ratings for Syros Pharmaceuticals
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Syros Pharmaceuticals?

Wall Street analysts have given Syros Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Syros Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Syros Pharmaceuticals' next earnings date?

Syros Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, March 4th 2021.
View our earnings forecast for Syros Pharmaceuticals
.

How were Syros Pharmaceuticals' earnings last quarter?

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) announced its quarterly earnings results on Thursday, November, 5th. The company reported ($0.43) EPS for the quarter, missing the Zacks' consensus estimate of ($0.38) by $0.05. The company had revenue of $3.83 million for the quarter, compared to the consensus estimate of $2.83 million. Syros Pharmaceuticals had a negative return on equity of 111.54% and a negative net margin of 743.58%.
View Syros Pharmaceuticals' earnings history
.

What price target have analysts set for SYRS?

8 brokerages have issued 12-month price objectives for Syros Pharmaceuticals' shares. Their forecasts range from $13.00 to $20.00. On average, they expect Syros Pharmaceuticals' share price to reach $17.57 in the next twelve months. This suggests a possible upside of 24.6% from the stock's current price.
View analysts' price targets for Syros Pharmaceuticals
or view Wall Street analyst' top-rated stocks.

Who are some of Syros Pharmaceuticals' key competitors?

What other stocks do shareholders of Syros Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Syros Pharmaceuticals investors own include Corbus Pharmaceuticals (CRBP), Sangamo Therapeutics (SGMO), Advanced Micro Devices (AMD), CRISPR Therapeutics (CRSP), ImmunoGen (IMGN), VBI Vaccines (VBIV), Amarin (AMRN), Amicus Therapeutics (FOLD), Nektar Therapeutics (NKTR) and Pfizer (PFE).

Who are Syros Pharmaceuticals' key executives?

Syros Pharmaceuticals' management team includes the following people:
  • Dr. Nancy A. Simonian, Pres, CEO & Director (Age 59, Pay $897.05k)
  • Dr. Richard A. Young, Scientific Founder, Member of Scientific Advisory Board & Director (Age 66, Pay $165k)
  • Dr. Eric R. Olson, Chief Scientific Officer (Age 62, Pay $638.63k)
  • Dr. David A. Roth, Chief Medical Officer (Age 57, Pay $641.48k)
  • Dr. Nathanael S. Gray Ph.D., Scientific Founder & Member of Scientific Advisory Board
  • Mr. Joseph J. Ferra Jr., Chief Financial Officer (Age 44)
  • Mr. Gerald E. Quirk, Chief Legal & Admin. Officer and Sec. (Age 52)
  • Ms. Naomi Aoki, VP of Corp. Communications & Investor Relations
  • Dr. Christian C. Fritz, Head of Biology
  • Dr. Jeremy P. Springhorn, Chief Bus. Officer (Age 58)

When did Syros Pharmaceuticals IPO?

(SYRS) raised $60 million in an IPO on Thursday, June 30th 2016. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Cowen and Company and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

What is Syros Pharmaceuticals' stock symbol?

Syros Pharmaceuticals trades on the NASDAQ under the ticker symbol "SYRS."

How do I buy shares of Syros Pharmaceuticals?

Shares of SYRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Syros Pharmaceuticals' stock price today?

One share of SYRS stock can currently be purchased for approximately $14.10.

How big of a company is Syros Pharmaceuticals?

Syros Pharmaceuticals has a market capitalization of $792.42 million and generates $1.98 million in revenue each year. The company earns $-75,440,000.00 in net income (profit) each year or ($1.88) on an earnings per share basis. Syros Pharmaceuticals employs 83 workers across the globe.

What is Syros Pharmaceuticals' official website?

The official website for Syros Pharmaceuticals is www.syros.com.

How can I contact Syros Pharmaceuticals?

Syros Pharmaceuticals' mailing address is 35 Cambridge Park Drive 4th Floor, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-744-1340 or via email at [email protected]

This page was last updated on 1/19/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.